Shawnte Mitchell - 02 Feb 2026 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Reporting relationship: CHIEF LEGAL OFFICER
Issuer ticker: OLMA
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2026, 21:30:06 UTC
Prior SEC filing: 03 Mar 2025
Next SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Shawnte Mitchell

Key filing fact

Shawnte Mitchell filed Form 4 for Olema Pharmaceuticals, Inc. (OLMA) on 04 Feb 2026.

Key facts

This page summarizes Shawnte Mitchell's Form 4 filing for Olema Pharmaceuticals, Inc. (OLMA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Feb 2026, 21:30.

Change

Previous filing in this sequence was filed on 03 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001749432 Primary reporting owner

Mitchell Shawnte

Relationship: CHIEF LEGAL OFFICER
Address: C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO
Signature: /s/ Shawnte Mitchell
Signature date: 04 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OLMA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +220,000
Change %
Price: $0.000000
Shares after: 220,000
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 220,000
Exercise price: $25.65
Footnotes: F1

OLMA transaction Derivative

Performance Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +56,250
Change %
Price: $0.000000
Shares after: 56,250
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 56,250
Exercise price: $25.65
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F2

The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.